ArticleDiscover oncology2025

Third-generation versus first-generation EGFR tyrosine kinase inhibitors in Asian patients with advanced EGFR mutant non-small cell lung cancer: a meta-analysis of randomized controlled trials.

Manzhen Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.